×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VTGN – vistagen therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VTGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
08:30 am
vtgn
Vistagen Appoints Nick Tressler as Chief Financial Officer
High
Report
Vistagen Appoints Nick Tressler as Chief Financial Officer
11/26
08:30 am
vtgn
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
Low
Report
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
11/18
07:58 am
vtgn
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]
Medium
Report
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]
11/17
12:08 pm
vtgn
VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
11/14
12:27 am
vtgn
Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]
Low
Report
Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]
11/13
07:07 pm
vtgn
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript [Seeking Alpha]
11/12
08:37 am
vtgn
What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings [Yahoo! Finance]
11/10
08:30 am
vtgn
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
Low
Report
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
04:30 pm
VTGN
vistagen therapeutics, inc.
MISS
Report
-0.3%
vistagen therapeutics, inc.
8/7/2025
04:30 pm
VTGN
vistagen therapeutics, inc.
IN-LINE
Report
8.0%
vistagen therapeutics, inc.
2/13/2025
04:30 pm
VTGN
vistagen therapeutics, inc.
BEAT
Report
6.5%
vistagen therapeutics, inc.
2/13/2025
04:30 pm
VTGN
vistagen therapeutics, inc.
BEAT
Report
6.5%
vistagen therapeutics, inc.
Date
Time
Symbol
Headline
Impact
12/4
06:07 am
vtgn
Form 4 Vistagen Therapeutics, For: Dec 01 Filed by: Tressler Nick B.
Medium
Report
Form 4 Vistagen Therapeutics, For: Dec 01 Filed by: Tressler Nick B.
12/4
06:06 am
vtgn
Form 3 Vistagen Therapeutics, For: Dec 01 Filed by: Tressler Nick B.
Medium
Report
Form 3 Vistagen Therapeutics, For: Dec 01 Filed by: Tressler Nick B.
12/3
04:47 pm
vtgn
Form 8-K Vistagen Therapeutics, For: Nov 28
High
Report
Form 8-K Vistagen Therapeutics, For: Nov 28
11/14
06:05 pm
vtgn
Form SCHEDULE 13G Vistagen Therapeutics, Filed by: ORBIMED ADVISORS LLC
High
Report
Form SCHEDULE 13G Vistagen Therapeutics, Filed by: ORBIMED ADVISORS LLC
11/14
04:46 pm
vtgn
Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: Nantahala Capital Management, LLC
High
Report
Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: Nantahala Capital Management, LLC
11/14
03:19 pm
vtgn
Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: GREAT POINT PARTNERS LLC
Neutral
Report
Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: GREAT POINT PARTNERS LLC
11/4
04:35 pm
vtgn
Form 4 Vistagen Therapeutics, For: Oct 27 Filed by: Edick Paul R
Low
Report
Form 4 Vistagen Therapeutics, For: Oct 27 Filed by: Edick Paul R
11/4
04:33 pm
vtgn
Form 3 Vistagen Therapeutics, For: Oct 27 Filed by: Edick Paul R
Low
Report
Form 3 Vistagen Therapeutics, For: Oct 27 Filed by: Edick Paul R
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
26.5%
3/25 VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million 24.6%
12/12 Form 8-K VistaGen Therapeutics, For: Dec 10 23.7%
7/23 VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray 11.1%
4/27 Form 4 VistaGen Therapeutics, For: Apr 23 Filed by: Underdown Brian J. 8.7%
11/8 Form 8-K VistaGen Therapeutics, For: Nov 07 8.0%
1/31 Form 8-K VistaGen Therapeutics, For: Jan 30 7.2%
8/1 Vistagen Therapeutics Inc (NASDAQ: VTGN) had its "neutral" rating re-affirmed by analysts at Chardan Capital. 6.3%
10/11 Vistagen Therapeutics Inc (NASDAQ: VTGN) was given a new $4.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 5.8%
12/12 Form D VistaGen Therapeutics, 5.4%
3/25 VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million 24.6%
12/12 Form 8-K VistaGen Therapeutics, For: Dec 10 23.7%
7/23 VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray 11.1%
4/27 Form 4 VistaGen Therapeutics, For: Apr 23 Filed by: Underdown Brian J. 8.7%
11/8 Form 8-K VistaGen Therapeutics, For: Nov 07 8.0%
1/31 Form 8-K VistaGen Therapeutics, For: Jan 30 7.2%
8/1 Vistagen Therapeutics Inc (NASDAQ: VTGN) had its "neutral" rating re-affirmed by analysts at Chardan Capital. 6.3%
10/11 Vistagen Therapeutics Inc (NASDAQ: VTGN) was given a new $4.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 5.8%
12/12 Form D VistaGen Therapeutics, 5.4%
TOP News Decliners
11/14
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
-72.7%
2/11 VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects -24.4%
2/20 VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder -21.6%
10/1 Form S-8 POS VistaGen Therapeutics, -15.9%
1/30 VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients -14.5%
12/28 Vistagen Therapeutics Inc (NASDAQ: VTGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -12.1%
4/15 Form 424B3 VistaGen Therapeutics, -11.8%
2/13 Form 10-Q VistaGen Therapeutics, For: Dec 31 -10.9%
10/9 Form 8-K VistaGen Therapeutics, For: Oct 08 -10.5%
7/23 Form DEF 14A VistaGen Therapeutics, For: Jul 26 -10.4%
2/11 VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects -24.4%
2/20 VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder -21.6%
10/1 Form S-8 POS VistaGen Therapeutics, -15.9%
1/30 VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients -14.5%
12/28 Vistagen Therapeutics Inc (NASDAQ: VTGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -12.1%
4/15 Form 424B3 VistaGen Therapeutics, -11.8%
2/13 Form 10-Q VistaGen Therapeutics, For: Dec 31 -10.9%
10/9 Form 8-K VistaGen Therapeutics, For: Oct 08 -10.5%
7/23 Form DEF 14A VistaGen Therapeutics, For: Jul 26 -10.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: